Genomic Testing Cooperative and its founder and CEO, Dr. Maher Albitar, were recently featured in the Houston Business Journal in a “Face to Face” profile highlighting GTC’s expansion to the Houston area and the company’s broader mission to advance precision oncology through genomic testing. The article discusses Dr. Albitar’s return to
New central U.S. location strengthens testing capacity and turnaround times while positioning GTC within the Texas Medical Center ecosystem HOUSTON — March 12, 2026 — Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions for hematologic neoplasm, solid tumors and liquid biopsy applications, today announced the opening
Lake Forest, CA — December 2, 2025 — Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions for hematologic tumors and liquid biopsy applications, today announced that its work and data will be presented in 12 abstracts at the ASH 2025 Annual Meeting
Summit Health Announces Internalization of GTC’s State-of-The-Art Next Gen Sequencing DNA & RNA Profiling Tests for Tissue and Liquid Biopsy of Solid Tumors and Hematologic Neoplasms Lake Forest, CA and Woodland Park, NJ – May 20, 2025 – Summit Health, part of Village MD and Genomic Testing Cooperative (GTC), the
Lake Forest, CA – April 8, 2025 – Genomic Testing Cooperative (GTC) today announced it received UKCA marks for its Hematology Profile Plus, Solid Tumor Plus as well as its Liquid Trace Hematology and Liquid Trace Solid Tumor for both solid tumors and hematology that provide comprehensive clinically actionable insights
Cologne, Germany and Lake Forest, CA. USA, March 18, 2025 – Labor Dr. Wisplinghoff one of Germanys largest and most renowned medical laboratories and Genomic Testing Cooperative (GTC), the global leader in RNA innovation, are excited to announce today the launch of their collaboration. With the innovative Next Generation Sequencing
Lake Forest, CA – November 13, 2024 – Genomic Testing Cooperative (GTC), a leader in advanced genomic testing, announced the launch of GTC Interpret, a new web-based platform designed to provide Co-Op member laboratories and partner labs seamless online access to fully analyze genomic data with sophisticated reporting tools. With
Manchester, NH – June 25, 2024 – BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the
San Antonio, TX and Irvine, CA – May 14, 2024 – CorePath Laboratories has selected Genomic Testing Cooperative (GTC) as a partner in next-generation sequencing (NGS) diagnostics for hematologic neoplasms and solid tumors in a long-term arrangement. Internalizing GTC’s tests has enabled CorePath pathologists to provide comprehensive evaluation of patient
Irvine, California– May 31, 2023 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting three studies illustrating the power of its proprietary RNA next generation sequencing (NGS) approach in advancing liquid biopsy and tissue-based precision testing.
